Table 3. Estimated incidence and disease burden of congenital toxoplasmosis (CT) in Denmark, 2014.
| Reported cases1 1999–2002 | Estimated cases | Duration years2 | Disability weight (Mean and 95% UI) | Total DALYs3 (Median and 95% UI) | ||
|---|---|---|---|---|---|---|
| Cases per 1,000 live births in 2014 (Median and 95% UI) | Total cases in 2014 (Median and 95% UI) | |||||
| Foetal loss ≥ 22 weeks of gestation |
- | - | 0.84 (0.6–1) | 92 | 1 | 78 (64–94) |
| Symptomatic in the first year of life | ||||||
| Chorioretinitis | 7 | 0.03 (0.01–0.06) | 2 (1–3) | 81 | 0.031 (0.019–0.049) | 5 (3–8) |
| Intracranial calcification | 10 | 0.04 0.02–0.07) | 3 (1–4) | 81 | 0.01* | 2 (1–3) |
| Hydrocephalus | 1 | 0.01 (0.001–0.02) | 0.40 (0–1) | 81 | 0.36 (0.16–0.56) | 13 (4–29) |
| CNS abnormalities | 1 | 0.01 (0.001–0.02) | 0.40 (0–1) | 81 | 0.36* | 14 (5–27) |
| Neonatal death4 | 0 | 0.0004 (0.0001–0.001) | 0.02 (0–0.03) | 92 | 1 | 2 (1–3) |
| Asymptomatic in the first year of life | ||||||
| Chorioretinitis later in life (Follow up to 12 years)5 | 6 | 0.05 (0.02–0.1) | 3 (1–5) | 69 | 0.031 (0.019–0.049) | 7 (4–11) |
| Total | - | - | - | - | - | 123 (100–148) |
DALYs, disability-adjusted life years; UI, uncertainty interval.
1Number of cases reported from the initial four years (1999–2002) of the Danish National Neonatal Screening Programme for CT (DNNSP[22,23]), which included >98% of newborns
2Duration of all health outcomes is life-long. We used the Danish life expectancy table (www.danmarksstatistik.dk/en) to estimate YLDs and the frontier national life expectancy projected for the year 2050 by the World Population Prospects 2012 (UN Population Division, 2013) [20] to estimate YLLs.
3Calculated as median incidence x duration x disability weight
4Minimum data from Denmark (zero neonatal deaths reported in initial four years [1999–2002] of DNNSP [23]); most likely and high value adapted from Havelaar et al. (2007) [18], giving an interval of 0.7% (0–1.2)
5Chorioretinitis later in life (at the age of 4–12 years) based on follow-up observations of The Danish Neonatal Feasibility Study (DNFS).
* No uncertainty interval available.